Prevacid NapraPAC Scripts Suggest PPI/NSAID Combos May Thrive Post-Vioxx
This article was originally published in The Tan Sheet
Executive Summary
TAP's Prevacid NapraPAC is among the early winners in the arthritis market following the withdrawal of Merck's Vioxx, IMS Health data suggest
You may also be interested in...
TAP Licenses Prevacid To Novartis For 2009 Switch
Novartis is developing TAP's Prevacid prescription heartburn and GERD therapy for a 2009 switch to OTC status, the firms announced Dec. 20
TAP Licenses Prevacid To Novartis For 2009 Switch
Novartis is developing TAP's Prevacid prescription heartburn and GERD therapy for a 2009 switch to OTC status, the firms announced Dec. 20
TAP Licenses Prevacid To Novartis For 2009 Switch
Novartis is developing TAP's Prevacid prescription heartburn and GERD therapy for a 2009 switch to OTC status, the firms announced Dec. 20